Editorial summary

The U.S. telehealth peptide market spans weight loss, recovery, longevity, cognitive enhancement, growth-hormone support, and sexual-health categories. Semaglutide and tirzepatide have FDA-approved brand-name versions for specific indications, while many peptide offerings discussed online are compounded or research-oriented and require careful clinical review. Compounded GLP-1 medications are not FDA-approved and are not the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®.

Browse by peptide

Weight Loss

Semaglutide

GLP-1 receptor agonist

Weight Loss

Tirzepatide

GIP/GLP-1 dual agonist

Weight Loss

Liraglutide

GLP-1 daily injection

Weight Loss

Retatrutide

GLP-1/GIP/glucagon triple agonist

Body Protection Compound-157

Recovery

TB-500

Thymosin Beta-4 fragment

Recovery

GHK-Cu

Copper peptide; skin and wound-healing research

Recovery

Pentadeca Arginate

BPC-157 arginate analog

Recovery

LL-37

Cathelicidin antimicrobial peptide

Recovery

KPV

alpha-MSH-derived anti-inflammatory tripeptide

Recovery

DSIP

Delta Sleep-Inducing Peptide

Longevity

NAD+

Nicotinamide adenine dinucleotide

Longevity

Epithalon

Tetrapeptide telomerase modulator

Longevity

MOTS-c

Mitochondrial-derived peptide

Longevity

SS-31

Elamipretide; mitochondrial protective peptide

Longevity

FOXO4-DRI

Senolytic peptide research compound

Longevity

Thymalin

Thymic peptide complex

Cognitive

Semax

Nootropic heptapeptide

Cognitive

Selank

Tuftsin analog used in anxiety/cognition research

Cognitive

Cerebrolysin

Porcine neuropeptide mixture

TREK-1 channel inhibitor research peptide

Growth Hormone

CJC-1295 / Ipamorelin

Combined GHRH analog + GHRP

FDA-approved GHRH analog for a specific indication

Growth Hormone

MK-677

Oral ghrelin mimetic / ibutamoren

Growth Hormone

IGF-1 LR3

Long-acting IGF-1 analog

Growth Hormone

Ipamorelin

Selective GH secretagogue

GH-releasing peptide; appetite stimulation

Growth Hormone

Hexarelin

Potent GH secretagogue

Sexual Health

PT-141

Bremelanotide / Vyleesi reference

Sexual Health

Oxytocin

Hormone used in selected clinical contexts

Sexual Health

Kisspeptin

Upstream HPG-axis activator

Browse by category

Category

Weight loss / GLP-1

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Category

Recovery & healing

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Category

Longevity

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Category

Cognitive enhancement

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Category

Growth hormone secretagogues

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Category

Sexual health

Browse peptide and medication profiles by therapeutic category with safety, regulatory, and telehealth availability context.

Most affordable GLP-1 programs reviewed

NexLife publishes transparent semaglutide and tirzepatide pricing.

Semaglutide from $165 monthly or $145/month on annual; tirzepatide from $215 monthly or $186/month on annual. Provider review and prescription required.

Check NexLife pricing

How to use this directory

Use these profiles as educational references, not as medical advice. A licensed clinician need to review medical history, contraindications, medication interactions, pregnancy status, and treatment goals before prescribing any medication or compounded preparation.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing

Peptide Directory

Browse by peptide

Browse by category

How to use this directory

Clinical evidence and access data

Trial outcome chart

Sources

Compare NexLife GLP-1 pricing